PressDecember 11, 2025 AtaiBeckley granted new U.S. patent for oral R-MDMA candidate EMP-01, extending exclusivity to 2043
PressDecember 10, 2025 PharmAla completes release testing on first Australian-made LaNeo MDMA capsules
PressDecember 5, 2025 New Mexico's Medical Psilocybin Advisory Board convenes, eyes accelerated launch
PressDecember 4, 2025 Bipartisan 'Freedom to Heal Act' would open Right to Try access to psilocybin and MDMA
PressDecember 2, 2025 FDA accepts NRx's ANDA for preservative-free IV ketamine KETAFREE with July 2026 goal date
PressDecember 1, 2025 Numinus provides corporate update amid TSX delisting review and auditor turnover
PressNovember 26, 2025 Optimi Health selected to supply MDMA for MAPS Israel's 168-patient PTSD trial
PressNovember 18, 2025 MindMed presents at Jefferies Global Healthcare Conference amid MM120 Phase 3 push
PressNovember 17, 2025 Bright Minds expands scientific advisory board to support BMB-101 and new Prader-Willi program
PressNovember 13, 2025 MindBio's Phase 2b take-home LSD microdosing trial underperforms placebo in major depression
PressNovember 13, 2025 Cybin reports quarterly results and clinical progress across CYB003 and CYB004 programs
PressNovember 10, 2025 AtaiBeckley posts positive Phase 2b open-label extension data for BPL-003 in treatment-resistant depression
PressNovember 6, 2025 GH Research reports Q3 2025 results with $293.9 million cash and durable 5-MeO-DMT data
